 | |
| Identifiers | |
|---|---|
3D model (JSmol) | |
| ChemSpider |
|
| |
| |
| Properties | |
| C19H29NO3 | |
| Molar mass | 319.445 g·mol−1 |
Except where otherwise noted, data are given for materials in theirstandard state (at 25 °C [77 °F], 100 kPa). | |
Dihydrotetrabenazine orDTBZ is anorganic compound with thechemical formula C19H29NO3. It is a close analog oftetrabenazine. DTBZ and its derivatives, when labeled withpositron emitting isotopes such ascarbon-11 andfluorine-18, are used asPETradioligands for examiningVMAT2.[1]
[11C]DTBZ as a PET radioligand with affinity for VMAT2 was developed in the mid 1990s byDavid E. Kuhl and colleagues at theUniversity of Michigan.[3] There are twoenantiomers of alpha-dihydrotetrabenazine, and thedextrorotary(or (+) isomer) has a highaffinity of about 1 nanomolar Ki whereas thelevorotary (or (-) isomer) has approximately 1000 fold lower affinity with a Ki of about 2 micromolar.[4]
VMAT2 is a membrane bound protein and abiomarker forParkinson's disease. Binding of DTBZ to VMAT2 in individuals withParkinson's disease is significantly reduced.[5] Moreover, the VMAT2 density as determined by [18F]DTBZ has been shown to be well, inversely correlated with the severity ofParkinson's disease.[6]
Avid Radiopharmaceuticals has sponsored clinical trials of [18F]AV-133 (or [18F]Fluoropropyl-(+)-DTBZ) to identify subjects with dopaminergic degeneration.[7]
